Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis

Arthritis and Rheumatism

Volumn 41, Issue 7, 1998, Pages 1203-1209

  Sharif, M ^a,c   Salisbury, C ^a   Taylor, D J ^b   Kirwan, J R ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOCHEMICAL MARKER; COLLAGENASE; CYTIDINE DEAMINASE; GLUCOCORTICOID; GLYCOSAMINOGLYCAN; HYALURONIC ACID; KERATAN SULFATE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PLACEBO; PREDNISOLONE; PROCOLLAGEN; STROMELYSIN;

ADULT; ARTICLE; BONE TURNOVER; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COLLAGENASES; CYTIDINE DEAMINASE; ENZYME PRECURSORS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PREDNISOLONE; PROCOLLAGEN;

EID: 0031809776     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199807)41:7<1203::AID-ART9>3.0.CO;2-2     Document Type: Article

References (31)

1. Empire Rheumatism Council. Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic in the long term treatment of rheumatoid arthritis. Ann Rheum Dis 1955;14:353-67.
2. Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960;19:331-7.
3. Byron MA, Kirwan JR. Corticosteroids in rheumatoid arthritis: is a trial of their 'disease modifying' potential feasible? Ann Rheum Dis 1986;46:171-3.
4. Byron MA, Mowat AG. Corticosteroid prescribing in rheumatoid arthritis - the fiction and the fact. Br J Rheumatol 1985;24:164-6.
5. Friesen WT, Hekster YA, van de Putte LBA, Gribnau FWJ. Cross-sectional study of rheumatoid arthritis treatment in a university hospital. Ann Rheum Dis 1985;44:272-8.
6. Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
7. Kirwan J, Hickling P, Jacoby R. Joint destruction recommences after glucocorticoids are withdrawn in early rheumatoid arthritis [abstract]. Arthritis Rheum 1996;39 Suppl 9:S218.
8. Butler RC, Davie MWJ, Worsfold M, Sharp CA. Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy. Br J Rheumatol 1991;30:86-90.
9. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
10. Williams JM, Downey C, Thonar EJ-MA. Increase in levels of serum keratan sulfate following cartilage proteoglycan degradation in the rabbit knee joint. Arthritis Rheum 1988;31:557-60.
11. Farndale RW, Buttle DJ, Barrett AJ. Improved quantification and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophys Acta 1986;883:173-7.
12. Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28: 1367-76.
13. Creamer P, Sharif M, George E, Cushnaghan J, Dieppe P. Intra-articular hyaluronic acid in osteoarthritis of the knee joint: an investigation into mechanisms of action. Osteoarthritis Cartilage 1994;2:133-40.
14. Engström-Laurent A, Hällgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985;43:83-8.
15. Engström-Laurent A, Hällgren R. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients: relationship to synovitis mass and morning stiffness. Arthritis Rheum 1987;30:1333-8.
16. Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thonar EJ-MA. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991;34: 799-807.
17. Goldberg RL. Enzyme-linked immunosorbent assay for hyaluronate using cartilage proteoglycan and an antibody to keratan sulphate. Anal Biochem 1988;174:448-58.
18. Hørslev-Petersen K, Kim KY, Pedersen LR, Bentsen KD, Uldbjerg N, Oxlund H, et al. Serum amino-terminal type III procollagen peptide: relation to biosynthesis of collagen type III in experimental induced granulation tissue in rats. APMIS 1988;96: 793-804.
19. Hørslev-Petersen K, Bentsen KD, Junker P, Lorenzen I. Serum amino-terminal type III procollagen peptide in rheumatoid arthritis: relationship to disease activity, treatment, and development of joint erosions. Arthritis Rheum 1986;29:592-9.
20. Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino-terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 month's treatment with levamisole, penidllamine, or azathioprine. Ann Rheum Dis 1988;47:116-26.
21. Sharif M, George E, Dieppe PA. Synovial fluid and serum concentrations of amino-terminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Ann Rheum Dis 1996;55:47-51.
22. Cormier C. Markers of bone metabolism. Curr Opin Rheumatol 1995;7:243-8.
23. Hanson DA, Weis MAE, Bollen AM, Malsan SH, Singer FR, Eyre DR. A specific immuno assay for monitoring human bone resorption: quantitation of type I collagen cross-link N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
24. Taylor DJ, Cheung NT, Davies PT. Increased serum proMMP-3 in inflammatory arthritis: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53:768-72.
25. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
26. Cawston T, Summers C, Powell L, Kavanagh R, Clark I, Hazleman B, et al. The measurement of TIMP, collagenase and TIMP-collagenase complex in osteoarthritic and rheumatoid synovial fluids [abstract]. Arthritis Rheum 1995;38 Suppl 9:S245.
27. Thompson PW, Jones DD, Currey HLF. Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis. Ann Rheum Dis 1986;45:9-14.
28. Jones DD, Roberts EL. Enzymes of DNA metabolism in clinical diagnosis. 2nd ed. Aberystwyth: Chancery Publications; 1986.
29. Cheung NT, Taylor DJ, Clarke S, Fisher J, Jones PW, Mattey DL, et al. Effect of 6 months treatment on serum pro-stromelysin and pro-collagenase levels in rheumatoid arthritis patients [abstract]. Br J Rheumatol 1996;35 Abstr Suppl 1:120.
30. Sedgwick AD, Moore AD, Al-Duail AY, Edwards JCW, Willoughby DA. Studies into the influence of carrageenan-induced inflammation on articular cartilage degradation using implantation into air-pouches. Br J Exp Pathol 1985;66:445-53.
31. Pettipher ER, Henderson B, Moncada S, Higgs GA. Leucocytes infiltration and cartilage proteoglycan loss in immune arthritis in the rabbit. Br J Pharmacol 1988;95:169-76.